| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Pediatric Oncology |
aDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; bDepartment of Pediatrics, University of Tennessee College of Medicine, Memphis, Tennessee, USA; cDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA
Key Words. Soft tissue sarcoma • Sarcoma • Child • Adolescent • Review
Correspondence: Correspondence: Sheri L. Spunt, M.D., St. Jude Children's Research Hospital, Department of Oncology, 332 N. Lauderdale Street, ALSAC-6032, Memphis, Tennessee 38105-2794, USA. Telephone: 901-495-3984; Fax: 901-521-9005; e-mail: sheri.spunt{at}stjude.org
Received October 1, 2007; accepted for publication April 8, 2008.
Disclosure: S.L.S. receives research funding from National Childhood Cancer Foundation/Children's Oncology Group. No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.
The nonrhabdomyosarcoma soft tissue sarcomas (NRSTSs) are a heterogeneous group of mesenchymal cell neoplasms that account for about 4% of childhood cancers. Because each histologic subtype of NRSTS is rare, they have been poorly studied and little is known about their biology, natural history, or optimal treatment. Data from adults with soft tissue sarcomas provide some helpful insight, but adult and childhood NRSTSs differ considerably in the distribution of their histologic subtypes, and certain entities are known to behave differently in young children. The greater risks posed to children by treatment, particularly by radiotherapy, also must be considered in treatment planning for children. This article summarizes what is known to date about childhood NRSTS, including the epidemiology, pathogenesis, and clinical approach to diagnosis and treatment of these tumors.
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |